NewsDialy
Eli Lilly has begun eliminating mandated price breaks for a few dozen hospitals enrolled in the federal 340B drug discount program, making good on a threat it issued earlier this month after those facilities failed to provide comprehensive claims data.
The drugmaker says the step is designed to eliminate what it calls duplicate discounts; hospital trade groups call the move unlawful and are urging Congress to intervene.
What the 340B Program Is — and What Lilly Is Requiring The 340B program is a federal drug discount program under which certain hospitals receive mandated price breaks from drug manufacturers.
Lilly announced in January that it would require participating hospitals to hand over claims data as a condition of continuing to receive those discounts, with the policy taking effect on Feb.
Keep reading